- Home
- TNGX vs ACLS Comparison
TNGX vs ACLS Comparison
Compare TNGX & ACLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | ACLS |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TNGX | ACLS |
|---|---|---|
| Price | $19.34 | $96.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $18.75 | ★ $101.50 |
| AVG Volume (30 Days) | ★ 3.7M | 676.2K |
| Earning Date | 03-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.89 | N/A |
| EPS | N/A | ★ 3.80 |
| Revenue | $62,384,000.00 | ★ $839,048,000.00 |
| Revenue This Year | N/A | $1.93 |
| Revenue Next Year | N/A | $7.91 |
| P/E Ratio | ★ N/A | $25.62 |
| Revenue Growth | ★ 48.29 | N/A |
| 52 Week Low | $1.04 | $40.40 |
| 52 Week High | $21.82 | $102.93 |
Technical Indicators
Market Signals| Indicator | TNGX | ACLS |
|---|---|---|
| Relative Strength Index (RSI) | 66.38 | 62.17 |
| Support Level | $6.77 | $78.24 |
| Resistance Level | N/A | $100.89 |
| Average True Range (ATR) | 1.12 | 4.05 |
| MACD | 0.09 | 1.67 |
| Stochastic Oscillator | 54.44 | 76.31 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.